Article
Preliminary Translational Results from an Ongoing Phase 1 Study of Flotetuzumab, a CD123 x CD3 Dart®, in AML/MDS: Rationale for Combining Flotetuzumab and Anti-PD-1/PD-L1 Immunotherapies
Blood
(2017)
Disciplines
Publication Date
December 7, 2017
DOI
10.1182/BLOOD.V130.SUPPL_1.1365.1365
Citation Information
Michael P Rettig, John Godwin, Norbert Vey, Bernard Fox, et al.. "Preliminary Translational Results from an Ongoing Phase 1 Study of Flotetuzumab, a CD123 x CD3 Dart®, in AML/MDS: Rationale for Combining Flotetuzumab and Anti-PD-1/PD-L1 Immunotherapies" Blood Vol. 130 (2017) p. 1365 - 1365 Available at: http://works.bepress.com/carlo-bifulco/73/